Riccardo Polosa
This has culminated with the participation of his research group in large EU funded pan-european research consortia (Unbiased BIOmarkers for the PREDiction of Respiratory Disease Outcome -U-BIOPRED; Airway Disease Predicting Outcomes through Patient Specific Computational Modelling – AIRPROM; Integral Rheumatology & Immunology Specialists Network – IRIS).
In 1996 he pursued Ph.D. in Internal Medicine at the University of Florence with a thesis on "The role of adhesion molecules in the inflammatory response of allergic asthma" (Supervisor: Prof. L. Mughini).
Since 2002 Polosa is a reviewer of the Italian Ministry of Health for ECM activities in the field of Respiratory Diseases and Clinical Immunology and Allergology.
[4] Polosa was appointed full professor of internal medicine at University of Catania in 2007 and was promoted as the director of the School of Specialization in Rheumatology in 2011.
[6][7][8][9] Riccardo Polosa was the principal investigator the first prospective randomized study with control group evaluating the efficacy and safety of electronic cigarettes on a sample of 300 smokers unwilling to quit.
He has led innovative research projects which, through the development of apps, provide daily support for diabetic patients to quit smoking.
DIASMOKE (Assessing the impact of combustion free-nicotine delivery technologies in Diabetic Smokers) is an international, multicenter, open-label randomized controlled study designed to determine whether diabetic smokers switching to combustion-free nicotine delivery systems (C-F NDS) experience measurable improvement in cardiovascular risk parameters as a consequence of avoiding exposure to cigarette smoke toxicants.
Among the most important papers, he published: COVID-19 and Obesity: Dangerous Liaisons; Seroepidemiological Survey on the Impact of Smoking on SARS-CoV-2 Infection and COVID-19 Outcomes: Protocol for the Troina Study; The effect of laboratory-verified smoking on SARS-CoV-2 infection: results from the Troina seroepidemiological survey; Smoking and SARS-CoV-2 Disease (COVID-19); Analytic modeling and risk assessment of aerial transmission of SARS-CoV-2 virus through vaping expirations in shared micro-environments Riccardo Polosa is the author of over 411 scientific publications[14] most of which are articles published in extenso in international scientific journals (H index equal to 56 –Citation Index total equal to 12104 - source: Scopus).
